State Street’s Tonix Pharmaceuticals TNXP Stock Holding History

State Street’s Portfolio TNXP Stock Details TNXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.46M	Buy	271,374 +40,767	+18%	+$526K	﹤0.01%	3159
2026 Q1	$3.17M	Buy	230,607 +38,752	+20%	+$597K	﹤0.01%	3145
2025 Q4	$3M	Buy	191,855 +39,311	+26%	+$725K	﹤0.01%	3202
2025 Q3	$3.69M	Buy	152,544 +29,287	+24%	+$1.09M	﹤0.01%	3111
2025 Q2	$4.43M	Buy	123,257 +103,204	+515%	+$2.7M	﹤0.01%	2999
2025 Q1	$358K	Buy	20,053 +19,722	+5,958%	+$400K	﹤0.01%	3680
2024 Q4	$10.9K	Buy	+331	New	+$6.88K	﹤0.01%	4275
2024 Q2	–	Sell	-10	Closed	-$5.8K	–	4396
2024 Q1	$5.8K	Hold	10	–	–	﹤0.01%	4349
2023 Q4	$12.6K	Hold	10	–	–	﹤0.01%	4383
2023 Q3	$17K	Hold	10	–	–	﹤0.01%	4461
2023 Q2	$49.3K	Hold	10	–	–	﹤0.01%	4421
2023 Q1	$115K	Buy	10 +8	+400%	+$137K	﹤0.01%	4277
2022 Q4	$18.6K	Hold	2	–	–	﹤0.01%	4741
2022 Q3	$25K	Hold	2	–	–	﹤0.01%	4793
2022 Q2	$75K	Sell	2 -10	-83%	-$738K	﹤0.01%	4625
2022 Q1	$1.71M	Buy	12 +2	+20%	+$306K	﹤0.01%	3626
2021 Q4	$2.39M	Hold	10	–	–	﹤0.01%	3584
2021 Q3	$3.99M	Buy	10 +2	+25%	+$974K	﹤0.01%	3349
2021 Q2	$5.66M	Buy	+8	New	+$5.88M	﹤0.01%	3188
2021 Q1	–	Hold	0	–	–	–	3903
2017 Q1	–	Hold	0	–	-$7K	–	3672
2016 Q4	–	Hold	0	–	–	–	3653
2016 Q3	–	Hold	0	–	–	–	3576
2016 Q2	–	Hold	0	–	–	–	3626
2016 Q1	–	Hold	0	–	–	–	3630

Other funds holding TNXP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ishara Investments Los Angeles, California $136M AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

State Street's TNXP Position: Q2 2026 in Review

State Street increased its Tonix Pharmaceuticals (TNXP) stake by 18% in Q2 2026, buying an estimated $526K and bringing the position to 271,374 shares worth $3.46M. The position accounts for ﹤0.01% of the portfolio, ranked #3159.

State Street first reported a position in TNXP in Q2 2021 and has held it in 19 quarters since. The position peaked at $5.66M in Q2 2021. 103 funds tracked by Wall St. Rank hold TNXP as of Q2 2026.

State Street held 271,374 shares of Tonix Pharmaceuticals worth $3.46M as of Q2 2026.
State Street bought 40,767 Tonix Pharmaceuticals shares in Q2 2026, an estimated $526K.
Tonix Pharmaceuticals made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3159 holding.
State Street first reported a position in Tonix Pharmaceuticals in Q2 2021 and has held it in 19 quarters since.
State Street's Tonix Pharmaceuticals position peaked at $5.66M in Q2 2021.
103 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.